Use of tumour-responsive T cells as cancer treatment
Authors:
- Mary L DisisMDMary L Disis
- Helga BernhardHBHelga Bernhard
- Elizabeth M JaffeeEJElizabeth M Jaffee
- 1 February 2009
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 373 (9664) , 673-683
Abstract
No abstract availableKeywords
This publication has 132 references indexed in Scilit:
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytesBlood, 2007
- Redirecting T lymphocyte specificity by T cell receptor gene transfer – A new era for immunotherapyMolecular Aspects of Medicine, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.Clinical Cancer Research, 2006
- Simultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell ReceptorCancer Research, 2005
- Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanomaHuman Immunology, 2004
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004